BACKGROUND: Single-agent arsenic trioxide has shown promising results in patients with relapsed or refractory multiple myeloma (MM). Because preclinical data suggested greater activity with dexamethasone and ascorbic acid, a phase 2 trial of the combination of arsenic trioxide, dexamethasone, and ascorbic acid in patients with relapsed or refractory MM was conducted. METHODS: Twenty patients in whom no more than two previous therapies had failed were enrolled. The mean age was 62 yr, and 55% of the patients had refractory disease. The regimen consisted of 14- or 15-wk cycles, with the first cycle considered induction, followed by one or two consolidation cycles with a reduced steroid schedule and then a maintenance cycle in responding patients. RESULTS: The overall response rate was 30%, with at least stable disease in 80% of patients. Median progression- free survival was 316 d in all patients and 584 d in those with a response. The regimen was well tolerated, with most adverse events being mild or moderate. CONCLUSIONS: This study showed the clinical efficacy and tolerability of the combination of arsenic trioxide, dexamethasone, and ascorbic acid. Further study is warranted.
BACKGROUND: Single-agent arsenic trioxide has shown promising results in patients with relapsed or refractory multiple myeloma (MM). Because preclinical data suggested greater activity with dexamethasone and ascorbic acid, a phase 2 trial of the combination of arsenic trioxide, dexamethasone, and ascorbic acid in patients with relapsed or refractory MM was conducted. METHODS: Twenty patients in whom no more than two previous therapies had failed were enrolled. The mean age was 62 yr, and 55% of the patients had refractory disease. The regimen consisted of 14- or 15-wk cycles, with the first cycle considered induction, followed by one or two consolidation cycles with a reduced steroid schedule and then a maintenance cycle in responding patients. RESULTS: The overall response rate was 30%, with at least stable disease in 80% of patients. Median progression- free survival was 316 d in all patients and 584 d in those with a response. The regimen was well tolerated, with most adverse events being mild or moderate. CONCLUSIONS: This study showed the clinical efficacy and tolerability of the combination of arsenic trioxide, dexamethasone, and ascorbic acid. Further study is warranted.
Authors: S L Soignet; S R Frankel; D Douer; M S Tallman; H Kantarjian; E Calleja; R M Stone; M Kalaycio; D A Scheinberg; P Steinherz; E L Sievers; S Coutré; S Dahlberg; R Ellison; R P Warrell Journal: J Clin Oncol Date: 2001-09-15 Impact factor: 44.544
Authors: N C Munshi; G Tricot; R Desikan; A Badros; M Zangari; A Toor; C Morris; E Anaissie; B Barlogie Journal: Leukemia Date: 2002-09 Impact factor: 11.528
Authors: Danka Cholujova; Zdenka Bujnakova; Erika Dutkova; Teru Hideshima; Richard W Groen; Constantine S Mitsiades; Paul G Richardson; David M Dorfman; Peter Balaz; Kenneth C Anderson; Jana Jakubikova Journal: Br J Haematol Date: 2017-10-19 Impact factor: 6.998
Authors: J E Chang; P M Voorhees; J M Kolesar; H G Ahuja; F A Sanchez; G A Rodriguez; K Kim; J Werndli; H H Bailey; B S Kahl Journal: Hematol Oncol Date: 2009-03 Impact factor: 5.271
Authors: Shannon M Matulis; Alejo A Morales; Lucy Yehiayan; Kelvin P Lee; Yong Cai; Lawrence H Boise Journal: PLoS One Date: 2012-12-21 Impact factor: 3.240